10-Q: Adtalem Global Education Reports Q3 2024 Results, Revenue Up 11.8%

Adtalem Global Education saw a significant revenue increase of 11.8% in the third quarter of fiscal year 2024, driven by growth across its Chamberlain, Walden, and Medical and Veterinary segments.

Summary

• Adtalem Global Education's revenue increased by 11.8% to $412.7 million in Q3 2024, compared to $369.1 million in Q3 2023.
• Net income for Q3 2024 was $36.8 million, or $0.93 per diluted share, a decrease from $45.9 million in the same period last year.
• Adjusted net income rose by 15.1% to $59.4 million in Q3 2024, compared to $51.6 million in Q3 2023.
• Diluted adjusted earnings per share increased by 32.7% to $1.50 in Q3 2024.
• Chamberlain University's enrollment increased by 7.0% in January 2024 and 9.0% in March 2024 compared to the same sessions last year.
• Walden University's total student enrollment increased by 8.4% as of March 31, 2024, compared to March 31, 2023.
• Enrollment at the medical and veterinary schools decreased by 4.5% in January 2024 compared to the same semester last year.
• The company repurchased 1,771,603 shares of its common stock at an average price of $51.60 per share during Q3 2024.
• Adtalem completed its thirteenth share repurchase program on January 16, 2024, and authorized a fourteenth program for up to $300 million through January 16, 2027.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is positive, the decrease in net income and the regulatory challenges create some uncertainty. The company's active share repurchase program and positive enrollment trends are encouraging, but the overall sentiment is cautiously optimistic.

Positives

• Revenue growth was strong across all three segments: Chamberlain, Walden, and Medical and Veterinary.
• Adjusted net income and diluted adjusted earnings per share showed significant increases.
• Enrollment at Chamberlain and Walden Universities demonstrated positive growth.
• The company is actively repurchasing shares, indicating confidence in its financial position.

Negatives

• Net income decreased by $9.0 million compared to the same period last year.
• Enrollment at the medical and veterinary schools decreased by 4.5% in January 2024.
• The income tax provision increased due to a higher percentage of earnings from domestic operations and the absence of a tax valuation allowance release recorded in the year-ago period.

Risks

• The company is subject to lawsuits, administrative proceedings, regulatory reviews, and investigations.
• The company's composite score declined to 0.2, resulting in provisional certifications with heightened cash monitoring.
• The company is subject to the risk of short selling strategies that may drive down the market price of its common stock.
• The company is subject to the risk of changes to financial aid programs that restrict student eligibility or reduce funding levels.

Future Outlook

The company expects to incur additional business integration expenses through the remainder of fiscal year 2024 at a decreasing rate and anticipates full fiscal year 2024 capital spending to be in the $65 to $70 million range.

Management Comments

• Management believes Chamberlain is achieving growth through leveraging scale and national footprint and providing a full breadth of nursing programs and modalities.
• Management believes Waldens performance turnaround in enrollment in the first nine months of fiscal year 2024 has been accelerated by investments in student experience and brand along with providing flexibility to working adults through part-time and Tempo Learning competency-based programs.
• Managements plan to increase enrollment at the medical and veterinary schools centers around renewed focus on operational efficiency, specifically academic support and the enrollment experience.

Industry Context

The document highlights Adtalem's position as a leading healthcare educator in the U.S., with a focus on nursing, medical, and veterinary programs. The company's performance is influenced by factors such as student enrollment trends, tuition rates, and regulatory requirements related to financial aid programs.

Comparison to Industry Standards

• The document does not provide specific industry benchmarks for comparison.
• However, the company's performance can be compared to other publicly traded education companies, such as those in the for-profit higher education sector.
• The company's enrollment trends and financial results can be compared to those of competitors like Strategic Education, Inc. and Grand Canyon Education, Inc.

Legal Proceedings

• Walden was served with a complaint alleging violations of Title VI of the Civil Rights Act of 1964, the Equal Credit Opportunity Act, and other state laws.
• The parties in the Aljanal Carroll case agreed on a $28.5 million payment to resolve the issues, subject to court approval.
• A settlement was reached in the Rajesh Verma case for an immaterial amount, subject to court approval.
• ED sent notice to Chamberlain, RUSM, RUSVM, and Walden that it had received borrower defense to repayment applications filed by students.

Stakeholder Impact

• Shareholders may be impacted by the decrease in net income and the ongoing legal proceedings.
• Employees may be affected by restructuring charges and workforce reductions.
• Students may be impacted by changes in tuition rates and financial aid programs.
• Customers may be impacted by changes in program offerings and services.

Next Steps

• The company will continue to monitor and respond to borrower defense to repayment applications.
• The company will continue to incur business integration expenses related to the Walden acquisition.
• The company will continue to evaluate market conditions and other factors for future share repurchases.
• The company will continue to focus on operational efficiency and student experience to drive enrollment growth.

Key Dates

Keywords

Adtalem Global Education, Chamberlain University, Walden University, Medical and Veterinary Schools, Higher Education, Financial Results, Enrollment, Share Repurchase, Net Income, Revenue, EBITDA